Based on the encouraging results from SUSTAIN FORTE studies, Novo Nordisk has filed a label expansion request with European Medicines Agency (EMA) on 29th December 2020 to introduce 2.0 mg dose of already approved weekly-once Ozempic for treatment of hyperglycaemia [86]
The conservative protocol works well for people who have tried tirzepatide before and experienced significant nausea at 2.5 mg, people with a history of GI sensitivity, or anyone who simply wants the most cautious possible introduction to a dual-agonist peptide
Side Effects of DSIP DSIP is not approved for human use, and extensive clinical trials are lacking as of writing
Pathology of melanotic schwannoma
Quick Answer: Tirzepatide does not directly cause sleeplessness as a recognised adverse effect, though sleep disturbances may occur indirectly through gastrointestinal symptoms or metabolic changes
Also, inflammation in the blood vessels narrows them, increasing the risk of blood clots